Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts

NCT05329220 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT05329220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05329220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts
Lead sponsor
Bavarian Nordic
Phase
Phase 3
Overall status
Completed
Start date
August 30, 2022
Completion date
October 5, 2023
Enrollment
4,205 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 disease